Mineralocorticoid receptor activation plays a key role in cardiovascular disease and hypertension, which are particularly prevalent in diabetes mellitus; secondary hyperaldosteronism contributes to cardiac failure. Major intervention trials in heart failure have demonstrated unequivocal benefit from aldosterone receptor antagonism. Focused experimental studies in humans and in animal models of hypertension have shown that aldosterone blockade improves a number of pathogenic abnormalities including vascular endothelial dysfunction and altered baroreflex function, and prevents the development of cardiac hypertrophy and renal histological damage. Based on recent outcomes studies, the challenge is now to transfer the experimental evidence into clinical M practice.
Petersen S., Peto V., Rayner M. (2003) Coronary Heart Disease Statistics. Oxford: British Heart Foundation Health Promotion Research Group.
2.
National Library of Medicine and the National Institutes of Health.Medical Encyclopedia. Available at http://www.nlm.nih.gov/medlineplus/encyclopedia.html (Date accessed 15 October 2003).
3.
Department of Health. (2001) National Service Framework for Diabetes - National Service Framework for Diabetes Standards. London: Department of Health.
4.
Stamler J., Vaccaro O., Neaton JD, Wentworth D.Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16:434-44.
5.
British Heart Foundation Health Promotion Research Group. (2003) Coronary Heart Disease Statistics - British Heart Foundation Statistics Database 2003. London: British Heart Foundation.
6.
Davies JO, Freeman RHHistorical perspectives on the renin-angiotensin-aldosterone system and angiotensin blockade. Am J Cardiol1982 ; 49:1385-9.
Wehling M.Aldosterone specific membrane receptors, rapid activation of the sodium-hydrogen exchanger, and cardiovascular implications. Cardiovasc Res1995;29:167-71.
9.
Wang W.Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension1994;24:571-5.
10.
Schmidt BMW , Montealegre A., Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Endocrinol Metab1999;84:3528-33.
11.
Brilla CG, Matsubara LS, Weber KTAnti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldo teronism. J Mol Cell Cardiol1993;25:563-75.
12.
Schachter M.Aldosterone antagonism: new ideas, new drugs . Br J Cardiol2002;9:533-7.
13.
Gómez-Sánchez EP, Venkataraman MT, Thwaites D., Fort C.ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol1990;258:E649-E653.
14.
Tanabe A., Naruse M., Naruse K. et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension . Hypertens Res1997;20:8590.
15.
Rocha R., Stier CT Jr, Kifor I. et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy . Endocrinology2000;141:3871-8.
16.
Rocha R., Chander PN, Khanna K. et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertens1998;31:451-8.
17.
Sun Y., Zhang J., Lu L.Aldosterone-induced inflammation in the rat heart: role of oxidative stress . Am J Pathol2002;161:1773-81.
18.
Struthers ADPathophysiology of aldosterone and its antagonists . Fundam Clin Pharmacol2000;14:549-52.
19.
MacFayden RJ , Barr CS, Struthers ADAldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart failure patients. Cardiovasc Res1997 ;35:30-4.
20.
Duprez DA, De Buyzere ML, Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J1998;19:1371-6.
21.
Yamamoto K. , Burnett JC, Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension1996 ;28:988-94.
22.
Weber KT, Villarreal D.Aldosterone and antialdosterone therapy in congestive heart failure . Am J Cardiol1993;71:3A-11A.
23.
Cleland JGF , Dargie HJ, Hodsman GPCaptopril in heart failure. A double blind controlled trial. Br Heart J1984;52:530-5.
24.
Staessen J. , Lijnen P., Fagard R. et al. Rise in plasma concentration of aldosterone during long-term angiotensisn II suppression . J Endocrinol1981;91:457-65.
25.
McKelvie RS , Yusuf S., Pericak D. et al. for the RESOLVD Pilot Study Investigators.Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation1999;100:1056-64.
26.
The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991;325(5):293-302.
27.
CIBIS-II Investigators and Committees.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial . Lancet1999;353:9-13.
28.
Burnier M., Brunner HRAngiotensin II receptor antagonists. Lancet2000;355:637-45.
29.
Pfeffer MA, Swedberg K., Granger CBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003;362:759-66.
30.
Pitt B.`Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther1995;9:145-9.
31.
Pitt B., Zannad F., Remme WJ et al. for the Randomized Aldactone Evaluation Study Investigators.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999;341:709-17.
32.
Pitt B., Remme W., Zannad F. et al. for the Eplerenone Post-Acute MI Heart Failure Efficacy and Survival Study Investigators.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after MI. N Engl J Med2003;348:1309-21.
33.
Primatesta P. , Brookes M., Poulter NRImproved hypertension management and control - results from the Health Survey for England1998. Hypertens2001;38:827-32.
34.
Hiramatsu K. , Yamada T., Yukimura Y. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients . Arch Intern Med1981;141:1589-93.
35.
Lim PO, Jung RT, MacDonald TMIs aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens2002;16:153-8.
36.
Connell JMC , Fraser R., MacKenzie S., Davies E.Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension?Hypertension2003;41:993-9.
37.
Lim PO, Jung RT, MacDonald TMRaised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol1999;48:756-60.
38.
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertension2004;18:139-85. ( www.bhsoc.org).
39.
Lim PO, Young WF, MacDonald TMA review of the medical treatment of primary aldosteronism. J Hypertens2001;19:353-61.
40.
Foo R., O'Shaughnessy M., Brown MJHyperaldosteronism: recent concepts, diagnosis and management. Postgrad Med J2001;77:639-44.
41.
Lim PO, Jung RT, MacDonald TMRaised aldosterone to rennin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol1999;48:756-60.
42.
Stier CT, Koenig S., Lee DY et al. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone. Heart Dis2003;5: 102-18.
43.
Coleman CI, Reddy P., Song JC et al. Eplerenone: the first selective aldosterone receptor antagonist for the treatment of hypertension. Formulary2002;37:514-24.
44.
Anonymous.Eplerenone (Inspra) . Med Lett Drugs Ther2003; 45(1156):39-40.
45.
Weber MAClinical implications of aldosterone blockade. Am Heart J2002;144:S12-S18.
46.
White WB, Duprez D., St Hillaire R. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension2003;41:1021-6.
47.
Krum H., Nolly H., Workman D. et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension2002 ;40:117-23.
48.
Moore TD, Nawarskas JJ, Anderson JREplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis2003;5:354-63.
49.
Domenic A., Sica MDEplerenone: a new aldosterone receptor antagonist - are the FDA's restrictions appropriate? J Clin Hypertens2002; 4(6):441-5.
50.
Haffner SM, Lehto S., Rónnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior MI. N Engl J Med1998;339:229-34.
51.
The Hypertension in Diabetes Study Group.Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens1993;11:309-17.
52.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703-13.
53.
Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998 ;351:1755- D62.
54.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.
55.
Yusuf S., Sleight P., Pogue J. et al. for the Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med2000;342:145-53.
56.
Lewis EJ, Hunsicker LG, Clarke WR et al. for the Collaborative Study Group.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851-60.
57.
Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJVisceral obesity and insulin resistance are associated with plasma aldosterone levels in women . Obes Res1999;7:355-62.
58.
Epstein M., Buckalew V., Martinez F. et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens2002;15 (4 part 2):24A. Abstract OR-54.
59.
White WB, Duprez D., St Hillaire R. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension2003;41:1021-6.
